Hematologic Diseases
Conditions
Brief summary
We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.
Interventions
PROCEDURESkin Biopsy
PROCEDUREBlood Draw
Sponsors
Stanford University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 18 years of age or older 2. Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined. 3. Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
Exclusion criteria
1. Less than 18 years of age 2. Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression | sample collection at time of routine visit |
Countries
United States
Outcome results
None listed